Phenotypic analysis of T cells infiltrating colon cancers: Correlations with oncogenetic status

References

• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-60; PMID:15032581; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104803
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-66; PMID:16371631; http://dx.doi.org/10.1056/NEJMoa051424
   PubMed Web of Science ®Google Scholar
• Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383: 1490-502; PMID:24225001; http://dx.doi.org/10.1016/S0140-6736(13)61649-9
   PubMed Web of Science ®Google Scholar
• Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology 2010; 138: 2059-72; PMID:20420946; http://dx.doi.org/10.1053/j.gastro.2009.12.065
   PubMed Web of Science ®Google Scholar
• Manne U, Shanmugam C, Katkoori VR, Bumpers HL, Grizzle WE. Development and progression of colorectal neoplasia. Cancer Biomark 2010; 9: 235-65; PMID:22112479
   PubMed Web of Science ®Google Scholar
• Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60; PMID:20018966; http://dx.doi.org/10.1056/NEJMra0804588
   PubMed Web of Science ®Google Scholar
• Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol 2012; 27: 1423-31; PMID:22694276; http://dx.doi.org/10.1111/j.1440-1746.2012.07200.x
   PubMed Web of Science ®Google Scholar
• Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-87 e3; PMID:20420947; http://dx.doi.org/10.1053/j.gastro.2009.12.064
   PubMed Web of Science ®Google Scholar
• Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-9; PMID:19571295; http://dx.doi.org/10.1056/NEJMc0904160
   PubMed Web of Science ®Google Scholar
• Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34; PMID:24024839; http://dx.doi.org/10.1056/NEJMoa1305275
   PubMed Web of Science ®Google Scholar
• Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010; 15: 390-404; PMID:20350999; http://dx.doi.org/10.1634/theoncologist.2009-0233
   PubMed Web of Science ®Google Scholar
• Tougeron D, Fauquembergue E, Latouche JB. [Immune response and colorectal cancer]. Bull Cancer 2013; 100: 283-94; PMID:23501583
   PubMed Web of Science ®Google Scholar
• Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, Dulphy N, Caillat-Zucman S, Paul P, Gornet JM, Douay C, et al. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 2007; 132: 2346-58; PMID:17570210; http://dx.doi.org/10.1053/j.gastro.2007.03.025
   PubMed Web of Science ®Google Scholar
• Pariente B, Mocan I, Camus M, Dutertre CA, Ettersperger J, Cattan P, Gornet JM, Dulphy N, Charron D, Lémann M, et al. Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease. Gastroenterology 2011; 141: 217-26, 26 e1-2; PMID:21600899; http://dx.doi.org/10.1053/j.gastro.2011.03.061
   PubMed Web of Science ®Google Scholar
• Groh V, Smythe K, Dai Z, Spies T. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 2006; 7: 755-62; PMID:16732291; http://dx.doi.org/10.1038/ni1350
   PubMed Web of Science ®Google Scholar
• Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944-58; PMID:18836475; http://dx.doi.org/10.1038/onc.2008.272
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
   PubMed Web of Science ®Google Scholar
• Pernot S, Terme M, Voron T, Colussi O, Marcheteau E, Tartour E, Taieb J. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol 2014; 20: 3738-50; PMID:24833840; http://dx.doi.org/10.3748/wjg.v20.i14.3738
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29: 610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425
   PubMed Web of Science ®Google Scholar
• Maccalli C, Pende D, Castelli C, Mingari MC, Robbins PF, Parmiani G. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity. Eur J Immunol 2003; 33: 2033-43; PMID:12884870; http://dx.doi.org/10.1002/eji.200323909
   PubMed Web of Science ®Google Scholar
• McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I, Trowsdale J, Durrant LG. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 2009; 15: 6993-7002; PMID:19861434; http://dx.doi.org/10.1158/1078-0432.CCR-09-0991
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-92; PMID:19064967; http://dx.doi.org/10.1200/JCO.2008.18.7229
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 2014; 63: 67-72; PMID:24213679; http://dx.doi.org/10.1007/s00262-013-1490-y
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70; PMID:10647931; http://dx.doi.org/10.1016/S0092-8674(00)81683-9
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17; PMID:19339720; http://dx.doi.org/10.1056/NEJMoa0805019
   PubMed Web of Science ®Google Scholar
• Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-606; PMID:23094721; http://dx.doi.org/10.1056/NEJMoa1207756
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-9; PMID:18202412; http://dx.doi.org/10.1200/JCO.2007.12.5906
   PubMed Web of Science ®Google Scholar
• Benlloch S, Paya A, Alenda C, Bessa X, Andreu M, Jover R, Castells A, Llor X, Aranda FI, Massutí B. Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 2006; 8: 540-3; PMID:17065421; http://dx.doi.org/10.2353/jmoldx.2006.060070
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Raut CP, Rodriguez-Bigas MA. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers 2004; 20: 199-206; PMID:15528785; http://dx.doi.org/10.1155/2004/368680
   PubMed Web of Science ®Google Scholar
• Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 1995; 92: 3963-7; PMID:7732013; http://dx.doi.org/10.1073/pnas.92.9.3963
   PubMed Web of Science ®Google Scholar